Welcome to our dedicated page for SRX Health Solutions SEC filings (Ticker: SRXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SRx Health Solutions, Inc. (NYSE American: SRXH) files a range of SEC documents that together outline its evolving strategy, capital structure and planned combination with EMJ Crypto Technologies Inc. (EMJX). On this page, investors can review current reports on Form 8-K, registration statements on Form S-1 and S-1/A, and other filings that describe material agreements, financing transactions and listing-status developments.
In its 8-K filings, the company discloses the Share Exchange and Asset Transfer Agreement to acquire EMJX, CCC Crypto Corp. and related intellectual property assets, including technology that uses artificial intelligence to predict outcomes from data sets. These reports also cover stockholder approvals for a future name change to EMJX, Inc. and a planned ticker change to EMJX, amendments to the Certificate of Incorporation to increase authorized common shares, and the designation of Series A Convertible Preferred Stock with detailed rights and conversion terms.
SRXH’s registration statements on Form S-1 and S-1/A provide additional information on private placements of Series A Convertible Preferred Stock and warrants, as well as an equity line of credit arrangement with Keystone Capital Partners, LLC. These documents explain how the company may raise capital through the issuance of equity and equity-linked securities, and they discuss risks associated with ownership of its securities. Filings also address NYSE American continued listing standards, including notices of non-compliance related to stockholders’ equity and the exchange’s acceptance of the company’s plan to regain compliance.
Through Stock Titan, users can access these filings as they are made available on EDGAR and review them alongside AI-generated summaries that highlight key terms, structural features and risk considerations. This includes simplified explanations of complex documents such as 8-Ks describing material definitive agreements, S-1 registration statements detailing resale registrations and capital-raising arrangements, and governance-related amendments to the company’s charter and bylaws.
SRx Health Solutions, Inc. is registering up to 2,506,893,959 shares of common stock for resale by Keystone Capital Partners under a Common Share Purchase Agreement. These shares are outstanding or issuable to Keystone, which may sell them over time, and SRx will only receive cash when it sells shares to Keystone, not from Keystone’s subsequent resales.
The company also entered into a Share Exchange and Asset Transfer Agreement to acquire EMJ Crypto Technologies Inc., CCC Crypto Corp., and certain artificial-intelligence-based IP assets in an all‑stock transaction valued at approximately $55 million. Closing requires stockholder approval, NYSE American listing of the new shares, effectiveness of a Form S‑4 registration statement, accurate representations by all parties, and other customary conditions, and the deal may be terminated if not completed by June 30, 2026, with certain termination expense reimbursements capped at $300,000 each way.
SRx Health Solutions, Inc. entered into a Share Exchange and Asset Transfer Agreement to acquire EMJ Crypto Technologies Inc., CCC Crypto Corp. and related AI-driven trading intellectual property in an approximately $55 million all-stock transaction.
The IP Asset consists of worldwide intellectual property rights in technology that uses artificial intelligence to predict outcomes from data sets, including an algorithm designed to outperform Bitcoin and Ethereum based on trading volatility, together with associated software, data, know-how and related materials.
Closing is subject to customary conditions, including approval of the transaction by SRx stockholders, SEC effectiveness of a Form S-4 registering the common shares to be issued for resale, and NYSE American approval to list those shares. The agreement includes mutual termination rights through an End Date of June 30, 2026, and if it is terminated due to a party’s breach, the breaching side must reimburse the other parties’ transaction fees and expenses up to $300,000.
SRx Health Solutions, Inc. has filed an amended registration statement covering the resale of up to 2,506,893,959 shares of common stock by Keystone Capital Partners under an equity line of credit structure. These Keystone Purchase Shares are tied to a Common Share Purchase Agreement that, as amended, allows SRx to sell up to $1.0 billion of stock to Keystone, while this prospectus registers Keystone’s potential resales, from which SRx will not receive proceeds.
The registered shares represent approximately 91.9% of SRx’s fully diluted common stock as of the prospectus date, compared with 27,723,906 shares outstanding and 218,636,279 shares on a fully diluted basis. The company warns that full resale could significantly depress the trading price and make raising additional equity more difficult. SRx carries a going concern warning, is highly dependent on external financing, and has recently undertaken multiple financings, a merger with SRx Canada, Canadian restructuring proceedings, PIPE transactions, and a large increase in authorized shares to 5,000,000,000.
SRx Health Solutions Inc. (formerly Better Choice Company) files its annual report describing a transformed business now centered on the Halo premium pet food brand after winding down its legacy specialty pharmacy operations, which are reported as discontinued following bankruptcy. Continuing operations generated about $6.5 million in net sales for the year ended September 30, 2025, mainly through e‑commerce partners like Amazon and Chewy, with smaller contributions from brick‑and‑mortar and international channels. The company has a lean workforce of 10 full‑time and one part‑time employee and relies on a few key co‑manufacturers, with roughly 85% of inventory purchases sourced from three vendors. Management highlights a digital‑first growth strategy and extensive regulatory requirements for pet food, but also discloses a history of significant losses, limited liquidity, and an expectation that additional financing will be needed to fully execute its business plan and potentially reach positive cash flow.
A holder of SRXH common stock filed a notice of intent to sell 37,007 shares through Charles Schwab on the NYSE, with an aggregate market value of 14591.00 and an approximate sale date of 12/03/2025. The table reports 24,853,633 shares of this class outstanding. Most of the shares to be sold were originally acquired from the issuer as executive compensation between 2022 and 2024, with an additional 5,000 shares purchased in the open market on 11/20/2024 for cash.
SRx Health Solutions, Inc. reported that its stockholders approved, and the company filed, an amendment to its Certificate of Incorporation to significantly increase its authorized common stock. The number of authorized shares of common stock, par value $0.001 per share, was raised from 200,000,000 shares to 5,000,000,000 shares, while the authorized preferred stock remains at 4,000,000 shares. Stockholders approved the amendment on October 8, 2025, following a recommendation from the Board of Directors, and the change became effective upon filing with the Delaware Secretary of State on November 19, 2025. This change expands the company’s capacity to issue additional common shares in the future for potential financing, acquisitions, or other corporate purposes.
SRx Health Solutions (SRXH) appointed Sammy Dorf to its Board of Directors, effective immediately. Dorf is Executive Chairman of Flora Growth and previously co-founded Verano Holdings, a multi-state cannabis company. The filing highlights his capital markets and operational experience, noting he has raised over $300 million and helped secure 25+ licenses across 14 states. The company also furnished a related press release as an exhibit.
SRx Health Solutions, Inc. filed a Form S-1 to register the resale of up to 101,865,909 shares of common stock by selling stockholders. This is a secondary offering; the company will not receive proceeds from any sales under this prospectus. The registered shares comprise multiple sources, including shares issuable upon conversion of Series A Preferred Stock and upon exercise of warrants issued in the July and October 2025 PIPE financings, exchangeable shares from SRx Canada, a prior private placement, service provider issuances, and shares issued in a share exchange.
The filing notes that these shares represent a considerable percentage of the public float and that resales could pressure the market price. Shares of common stock outstanding were 24,992,539 as of November 5, 2025; this is a baseline figure, not the amount being offered. SRXH is listed on NYSE American. The company states it will not receive any proceeds from selling stockholders’ resales and highlights risks related to future capital needs, potential dilution from future financings, and other operational and market factors.
SRx Health Solutions, Inc. filed an S-1 registering up to 82,000,000 shares of common stock for resale by Keystone Capital Partners. These shares are outstanding or issuable under a Common Share Purchase Agreement, and the Selling Stockholder will receive all proceeds from any resales. We are not selling securities in this prospectus and will not receive proceeds from the Selling Stockholder’s sales.
The Company may, at its discretion, sell shares to Keystone under an equity line, with potential aggregate gross proceeds of up to $1.0 billion subject to agreement terms and market conditions. The 82,000,000 shares offered for resale represent approximately 40.64% of total fully diluted outstanding shares as of this prospectus. Shares outstanding were 24,992,539 as of October 31, 2025. Our common stock trades on NYSE American under “SRXH”; the October 31, 2025 closing price was $0.3000 per share.
The filing notes NYSE American’s 19.99% Exchange Cap and a 4.99% beneficial ownership limit applicable to the Selling Stockholder. The Company will pay certain registration expenses; sale methods are as described under Plan of Distribution.
SRx Health Solutions entered a private placement for up to $30.46 million of Series A convertible preferred stock and accompanying warrants, with an initial closing on October 31, 2025. At the first closing, investors purchased 19,035 Series A shares and 54,527,811 warrants for aggregate proceeds of approximately $15.23 million, paid in cash or through cancellation of prior instruments.
The warrants expire three years from first exercisability and have an exercise price of $0.6109, subject to adjustments as described. The Series A Preferred is convertible at a fixed price of $0.6109, with an alternate conversion formula during specified triggering events, bounded by a floor price of $0.6109. The company will seek stockholder approval to increase authorized common shares from 200,000,000 to 5,000,000,000.
The company also amended its common stock purchase agreement, increasing the total commitment from $50 million to $1 billion, and issued a $20 million convertible promissory note. Two directors resigned effective October 31, 2025, with no disagreements noted, and board committees were reconstituted.